Achyrocline satureioides (As) (known as Marcela) is a plant belonging to the family Asteraceae, with a high content of flavonoids, which justifies its antioxidant and anti-inflammatory properties. Previous clinical studies confirm that compounds with these actions have beneficial effects on patients with Obstructive Sleep Apnea Syndrome (OSAS). This double-blind pilot study investigates the influence of chronic oral treatment (3 months duration) with a preparation of As on some sleep parameters. Eight patients selected as do not possess of other pathologies were diagnosed with OSAS by standard polysomnography (PSG) (5 treated with As and 3 with placebo). As extract used containing 3 mg/ml of the flavonoid quercetin, measured by HPLC, and a prepared without As was used as placebo. Another PSG was performed at the end of the study. The results showed a statistically significant increase of REM sleep (Stage R, 125% increase) and an increasing trend in N2 and N3 stages (slow wave sleep) in patients treated with As. Untreated patients showed random results. The Epworth Sleepiness Scale decreased significantly, which means better quality of life and waking. There were no changes in rates of apnea/hypopnea or oximetry. Improving the quality of sleep and wakefulness, but not a direct influence on the parameters of OSAS, could be justified by the antioxidant and anti-inflammatory actions described for polyphenols, contents in preparations of As.